Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CTH | P32929 | 1/20 | 0.34 |
| ▸ | CBS | P35520 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1562866 | 0.79 | — | — | |
| SCHEMBL14538253 | 0.73 | GAA (0.44) | THRBSMN1; SMN2LMNAGAAHPGD | |
| SCHEMBL31308086 | 0.73 | TSHR (0.36) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL19227961 | 0.69 | — | — | |
| SCHEMBL20034909 | 0.67 | FAAH (0.37) | TSHRSMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL17462016 | 0.67 | LMNA (0.35) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL13798262 | 0.67 | LMNA (0.49) | SMN1; SMN2LMNAGAAHPGDKDM4E | |
| SCHEMBL13531995 | 0.67 | FAAH (0.40) | THRBSMN1; SMN2ALDH1A1 | |
| SCHEMBL16158618 | 0.67 | TSHR (0.33) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL1105653 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | TSHR 3853/4885CTH 4158/4885CBS 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.